These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24915263)

  • 1. Insulin therapy for type 2 diabetes mellitus.
    Wallia A; Molitch ME
    JAMA; 2014 Jun; 311(22):2315-25. PubMed ID: 24915263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
    Vinik A
    Clin Ther; 2007 Jun; 29(6 Pt 1):1236-53. PubMed ID: 18036387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized intensification of insulin therapy in type 2 diabetes - does a basal-bolus regimen suit all patients?
    Giugliano D; Sieradzki J; Stefanski A; Gentilella R
    Curr Med Res Opin; 2016 Aug; 32(8):1425-34. PubMed ID: 27126277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure.
    Davidson MB; Raskin P; Tanenberg RJ; Vlajnic A; Hollander P
    Endocr Pract; 2011; 17(3):395-403. PubMed ID: 21324825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year efficacy of complex insulin regimens in type 2 diabetes.
    Holman RR; Farmer AJ; Davies MJ; Levy JC; Darbyshire JL; Keenan JF; Paul SK;
    N Engl J Med; 2009 Oct; 361(18):1736-47. PubMed ID: 19850703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of timely basal insulin control in patients with type 2 diabetes.
    Lovre D; Fonseca V
    J Diabetes Complications; 2015 Mar; 29(2):295-301. PubMed ID: 25536866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes.
    Vos RC; Rutten GEHM
    JAMA; 2017 Oct; 318(15):1489-1490. PubMed ID: 29049639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensifying insulin therapy: what options are available to patients with type 2 diabetes?
    Meneghini LF
    Am J Med; 2013 Sep; 126(9 Suppl 1):S28-37. PubMed ID: 23953077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
    Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to rapid acting insulin intensification in patients with type 2 diabetes mellitus not achieving glycemic targets.
    Migdal A; Abrahamson M; Peters A; Vint N
    Ann Med; 2018 Sep; 50(6):453-460. PubMed ID: 30103624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups.
    Sidorenkov G; van Boven JFM; Hoekstra T; Nijpels G; Hoogenberg K; Denig P
    Diabetes Obes Metab; 2018 Aug; 20(8):1957-1964. PubMed ID: 29687577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review.
    DeWitt DE; Hirsch IB
    JAMA; 2003 May; 289(17):2254-64. PubMed ID: 12734137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
    Hunt B; Mocarski M; Valentine WJ; Langer J
    J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
    Lane W; Weinrib S; Rappaport J
    Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Insulin Therapy: Basal Insulin and Beyond.
    Aroda V; Johnson EL; Novak L; Skolnik N
    J Fam Pract; 2018 Oct; 67(10 Suppl):. PubMed ID: 30423012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.
    Khunti K; Nikolajsen A; Thorsted BL; Andersen M; Davies MJ; Paul SK
    Diabetes Obes Metab; 2016 Apr; 18(4):401-9. PubMed ID: 26743666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Type 2 diabetes: hypoglycemia risk, weight gain... Will there soon be a new alternative to insulin?].
    MMW Fortschr Med; 2006 Sep; 148(37):54. PubMed ID: 17036907
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.